# Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

> **NCT05172180** · — · COMPLETED · sponsor: **POLYSAN Scientific & Technological Pharmaceutical Company** · enrollment: 105 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Reamberin
- **DRUG:** Ringer's solution

## Key facts

- **NCT ID:** NCT05172180
- **Lead sponsor:** POLYSAN Scientific & Technological Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-04-01
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172180, "Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05172180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*